Research progress on the role of NLRP3 inflammasome in hematological malignancies

BAI Xiao-teng, SUN Xiao-hong, ZHAO Xiang-yu, LI Zi-jian

PDF(836 KB)
Welcome to Current Immunology, Today is May. 15, 2025
PDF(836 KB)
Current Immunology ›› 2023, Vol. 43 ›› Issue (3) : 257-262.

Research progress on the role of NLRP3 inflammasome in hematological malignancies

  • BAI Xiao-teng1, SUN Xiao-hong1, ZHAO Xiang-yu1, LI Zi-jian2
Author information +
History +

Abstract

The human immune system includes innate immunity and adaptive immunity. Innate immune cells recognize dangerous endogenous and exogenous antigens through PRR. PRR include TLR, NOD-like receptors (NLR) and C-type lectin receptors (CLR), etc. NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome belongs to the NLR family and as the core of inflammatory response, it is closely related to the occurrence and development of many malignant tumors, including multiple hematological tumors. This article reviews the latest research progress on the relationship between NLRP3 inflammasome and lymphoma, leukemia, myelodysplastic syndrome, and multiple myeloma.

Key words

lymphoma / leukemia / myelodysplastic syndrome / multiple myeloma / NOD-like receptor family pyrin domain-containing protein 3

Cite this article

Download Citations
BAI Xiao-teng, SUN Xiao-hong, ZHAO Xiang-yu, LI Zi-jian. Research progress on the role of NLRP3 inflammasome in hematological malignancies. Current Immunology. 2023, 43(3): 257-262
PDF(836 KB)

681

Accesses

0

Citation

Detail

Sections
Recommended

/